Navigation Links
FDA Approves First 3-D Mammography Imaging System
Date:2/11/2011

SILVER SPRING, Md., Feb. 11, 2011 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration today approved the Selenia Dimensions System, the first X-ray mammography device that provides three-dimensional (3-D) images of the breast for breast cancer screening and diagnosis.

(Logo:  http://photos.prnewswire.com/prnh/20090824/FDALOGO)

A mammogram is a safe, low-dose X-ray of the breast that is the best tool for early detection of breast cancer. However, with the limitations of conventional two-dimensional (2-D) imaging, about 10 percent of women undergo additional testing after the initial screening exam for abnormalities that are later determined to be noncancerous.

The Selenia Dimensions System, an upgrade to Hologic's existing FDA-approved 2-D system, can provide 2-D and 3-D X-ray images of the breasts. The 3-D images may help physicians more accurately detect and diagnose breast cancer.

"Physicians can now access this unique and innovative 3-D technology that could significantly enhance existing diagnosis and treatment approaches," said Jeffrey Shuren, M.D., J.D., director of the FDA's Center for Devices and Radiological Health.

The National Cancer Institute recommends women ages 40 and older have a mammogram every one to two years. Nearly 40 million mammograms are performed each year in the United States.

As part of the approval process, the FDA reviewed results from two studies where board-certified radiologists were asked to review 2-D and 3-D images from more than 300 mammography exams.  In both studies, radiologists viewing both the 2-D and 3-D images obtained a 7 percent improvement in their ability to distinguish between cancerous and non-cancerous cases as compared to viewing 2-D images alone.

While the combination of the Selenia's 2-D and 3-D images approximately doubled the radiation dose the patient received, it improved the accuracy with which radiologists detected cancers, decreasing the number of women recalled for a diagnostic workup. There is uncertainty for radiation risk estimates; however, the increase in cancer risk from having both a 2-D and 3-D exam is expected to be less than 1.5 percent compared to the natural cancer incidence, and less than 1 percent compared to the risk from conventional 2-D mammography.

The Mammography Quality Standards Act requires that all health care professionals obtain eight hours of training prior to using new mammography technology on patients. The FDA also requires that the manufacturer provide each facility with a manual clearly defining the tests required for initial, periodic, and yearly quality control measures.

According to the NCI, nearly 200,000 women will be diagnosed with breast cancer this year. And 1 in 8 women will be diagnosed with breast cancer during their lifetime. There is a 98 percent survival rate when breast cancer is detected early and still localized to the breast.

The Selenia Dimensions System is marketed by Bedford, Mass.-based Hologic Inc.

Media Inquiries: Erica Jefferson, 301-796-4988, erica.jefferson@fda.hhs.gov

Consumer Inquiries: 888-INFO-FDA




'/>"/>
SOURCE U.S. Food and Drug Administration
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. FDA Approves 1st Pacemaker Designed to Work Safely During Some MRI Exams
2. FDA Approves Hologics Makena™ (Formerly Referred to as Gestiva™) Pharmaceutical
3. FDA Approves Drug to Reduce Risk of Preterm Birth in At-Risk Pregnant Women
4. FDA Approves Makena™, the First and Only Treatment to Reduce the Risk of Preterm Birth in Women With a Singleton Pregnancy Who Have a History of Singleton Spontaneous Preterm Birth
5. FDA Approves Viibryd to Treat Major Depressive Disorder
6. FDA Approves Head Lice Treatment for Children and Adults
7. FDA Approves Opioid Analgesic to Help Cancer Patients Manage Pain
8. VIDEO from Endo Pharmaceuticals Available on thenewsmarket.com: FDA Approves New Treatment for Low Testosterone
9. FDA Approves New Dosage Strength for INTELENCE®
10. U.S. FDA Approves Second Bayer Oral Contraceptive That Also Raises Folate Levels
11. FDA Approves PREZISTA®/ritonavir Once-Daily Dosing for HIV-1 Treatment-Experienced Adults With No Darunavir Resistance-Associated Mutations
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... Research and Markets has announced the addition of the ... offering. ... Menopause Drugs Price Analysis and Strategies - 2016, provides drug pricing data ... following questions: What are the key drugs ... the Global Menopause market? What are the unit prices ...
(Date:2/23/2017)... 23, 2017 Regulus Therapeutics Inc . ... development of innovative medicines targeting microRNAs, today announced it ... results on Thursday, March 2, 2017 after the market ... and webcast on March 2, 2017 at 5:00 p.m. ... 2016 financial results and provide a general business update.  ...
(Date:2/23/2017)... -- The fast-growing cannabis market is expected to ... . According to the 2017 Legal Marijuana Outlook, published by ... 283,422 jobs by 2020, with an implied growth rate of ... The accelerating pace of cannabis legalization is considered as the ... which will further create more business ventures and boost the ...
Breaking Medicine Technology:
(Date:2/23/2017)... , ... February 23, 2017 , ... Dr. David Mahon ... Henderson, NV 89052. Dr. Mahon was named a 2017 Top Patient Rated Henderson ... is an online directory that recognizes local physicians and dentists who have earned high ...
(Date:2/23/2017)... ... February 23, 2017 , ... Healthcare Research ... those in the fight against cancer, has produced a seminal study that asked ... will release top-line findings in a webinar, Defining Compassionate Care Through the Voices ...
(Date:2/23/2017)... ... February 23, 2017 , ... Top cosmetic and periodontal dentist Dr. ... with a new Indiegogo campaign . Individuals are now able to contribute to ... Angeles area, either as a participating patient or through an Indiegogo donation. The entirety ...
(Date:2/23/2017)... Va. (PRWEB) , ... February 23, 2017 , ... ... or problems. He has also continued to spiritually evolve, which is the purpose of ... book “ Our Spiritual Truths ” (published by Balboa Press) attempts to guide readers ...
(Date:2/22/2017)... ... February 22, 2017 , ... Stem cell therapy has made ... is so cutting edge, in fact, the U.S. Food and Drug Administration (FDA) ... successful patient outcomes in certain clinical stem cell procedures have shown that this ...
Breaking Medicine News(10 mins):